<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To describe the frequency of MLH1 promoter methylation in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>); to explore the associations between MLH1 promoter methylation and clinicopathological and molecular factors using a systematic review and meta-analysis </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A literature search of the PubMed and Embase databases was conducted to identify relevant articles published up to September 7, 2012 that described the frequency of MLH1 promoter methylation or its associations with clinicopathological and molecular factors in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The pooled frequency, odds ratio (OR) and 95% confidence intervals (95% CI) were calculated </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The pooled frequency of MLH1 promoter methylation in unselected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was 20.3% (95% CI: 16.8-24.1%) </plain></SENT>
<SENT sid="4" pm="."><plain>They were 18.7% (95% CI: 14.7-23.6%) and 16.4% (95% CI: 11.9-22.0%) in <z:hpo ids='HP_0003745'>sporadic</z:hpo> and <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> (LS) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Significant associations were observed between MLH1 promoter methylation and gender (pooled OR = 1.641, 95% CI: 1.215-2.215; P = 0.001), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> location (pooled OR = 3.804, 95% CI: 2.715-5.329; P&lt;0.001), <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation (pooled OR = 2.131, 95% CI: 1.464-3.102; P&lt;0.001), MSI (OR: 27.096, 95% CI: 13.717-53.526; P&lt;0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>Significant associations were also observed between MLH1 promoter methylation and MLH1 protein expression, BRAF mutation (OR = 14.919 (95% CI: 6.427-34.631; P&lt;0.001) and 9.419 (95% CI: 2.613-33.953; P = 0.001), respectively) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: The frequency of MLH1 promoter methylation in unselected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was 20.3% </plain></SENT>
<SENT sid="8" pm="."><plain>They were 18.7% in <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and 16.4% in LS <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>MLH1 promoter methylation may be significantly associated with gender, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> location, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> differentiation, MSI, MLH1 protein expression, and BRAF mutation </plain></SENT>
</text></document>